Drug Trial Radar · NCT03013218
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
Last checked: Nov 19, 2026Latest source record: Aug 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
174
Actual
Start
Feb 3, 2017
Primary completion
Feb 1, 2022
Study completion Jul 8, 2025
Sponsor
- Lead sponsor
- ALX Oncology Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 6, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase 1, dose escalation study of evorpacept (ALX148) in patients with advanced solid tumors and lymphoma
Conditions
- Metastatic Cancer
- Solid Tumor
- Advanced Cancer
- NonHodgkin Lymphoma
Interventions
Evorpacept (ALX148)Drug
Evorpacept (ALX148)
PembrolizumabDrug
Keytruda
TrastuzumabDrug
Herceptin
RituximabDrug
Rituxan
Ramucirumab + PaclitaxelDrug
Standard of care chemotherapy
5-FU + CisplatinDrug
Standard of care chemotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicities (Number of participants with a DLT)Time frame: Up to 28 days
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
University of Colorado Denver
Denver, Colorado
Yale University
New Haven, Connecticut
Massachusetts General Hospital
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
START-Midwest
Grand Rapids, Michigan
Seattle Cancer Care Alliance
Seattle, Washington
Seoul National University Bundang Hospital
Seongnam, South Korea
Samsung Medical Center
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital, Yonsei University
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.